Olivier Hequet
University of Lyon
56 Papers
336 Citations
Olivier Hequet is an academic researcher from University of Lyon. The author has contributed to research in topics: Medicine & Transplantation. The author has an hindex of 20, co-authored 52 publications. Previous affiliations of Olivier Hequet include American Society of Clinical Oncology.
Chat about Author
Papers
Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients
François Lefrère,Dominique bastit-Barrau,Olivier Hequet,Philippe Bourin,Suzanne Mathieu-Nafissi,Alain Bohbot,Hervé Tilly,Gilles Salles,Christophe Fermé,Valérie Lapierre,Luc Fornecker,Jean-Michel Miclea,Loic Isebaert,Serge Bologna,Olivier Fitoussi,Nicolas Mounier,Corinne Haioun +16 more
TL;DR: The impact of rituximab on stem cell mobilization in two similar consecutive groups of patients treated with ACVBP in two prospective, controlled trials is assessed.
6
Mesenchymal stem cell and immunosuppressive drug interactions.
Fanny Buron,Emmanuel Morelon,Hélène Perrin,Christophe Malcus,Françoise Touraine Moulin,Olivier Hequet +5 more
TL;DR: The authors thank Eddie Takahashi for the English translation and Lippincott Williams & Wilkins for the translation of the manuscript.
6
Red blood cell exchange in children and adolescents with sickle cell disease
TL;DR: This review summarizes the limits, safety precautions and the adaptations of the techniques to ensure RBCX in children.
5
Treatment of severe refractory de novo auto-immune hepatitis after liver transplantation with plasmapheresis.
Jérôme Dumortier,Jean-Yves Scoazec,Olivier Guillaud,Olivier Hequet,Valérie Hervieu,Olivier Boillot +5 more
TL;DR: A case of a liver transplanted young female patient who presented a severe de novo AIH, refractory to tacrolimus, mycophenolate mofetil and steroids, and who was treated with plasmapheresis is reported.
5
A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors
Charles Dumontet,Catherine Thieblemont,Daniel Espinouse,Fadhela Bouafia,Olivier Hequet,Gilles Salles,Bertrand Coiffier +6 more
TL;DR: Early therapeutic intensification after intensive induction chemotherapy is feasible in patients with poor prognosis aggressive NHL and shows promising response and survival rates.
5